Antidepressant Selection in a 71-Year-Old with Geriatric Depression, ITP, and AF on Apixaban + Bisoprolol

Clinical Summary of Concerns

1. Geriatric pharmacology - "start low, go slow," risk of hyponatremia (SIADH), falls, polypharmacy
2. ITP - baseline platelet dysfunction; any agent that further impairs platelet function is hazardous
3. Atrial fibrillation on Apixaban - DOAC + SSRI combination carries augmented bleeding risk; CYP interactions matter
4. Bisoprolol (beta-blocker) - some antidepressants affect CYP2D6, which metabolises bisoprolol (a CYP2D6 substrate); strong 2D6 inhibitors (paroxetine, fluoxetine) can increase bisoprolol levels and cause bradycardia/hypotension

First-Line Recommendation: Sertraline

Why Sertraline?

"Clinical practice guidelines recommend that SSRIs and other second-generation antidepressants are the first-line treatment for late-life depression."

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry

• Sertraline: No significant effect on QTc interval, minimal effect on heart rate/BP, no arrhythmia risk, no conduction disturbance. Described as "safe post-MI and in heart failure" - the best cardiac profile of any SSRI.
• By contrast: Citalopram and Escitalopram show dose-related QTc prolongation (a problem in AF patients already at arrhythmia risk), and Paroxetine inhibits CYP2D6 strongly - raising bisoprolol plasma levels and risking bradycardia.

• The drugs.com interaction checker flags a moderate sertraline-thrombocytopenia warning
• However, all SSRIs share this mechanism; mirtazapine and bupropion were not found to significantly reduce bleeding risk compared to SSRIs in meta-analysis (OR ~1.0)
• Since the patient is stable with regular bloods and no active bleeding, this risk is manageable with monitoring

Strong Second-Line Option: Mirtazapine

• Mirtazapine's NaSSA mechanism (alpha-2 antagonist + 5-HT2/3 blocker) gives it strong sedative and anxiolytic properties without serotonin transporter blockade - theoretically less platelet effect
• Cardiac profile: No QTc effect, minimal heart rate/BP changes, "Evidence of safety post MI. Good alternative to SSRIs" - Maudsley Table 3.13
• Addresses insomnia and low appetite (common in geriatric depression) due to histamine H1 blockade at low doses (7.5-15 mg nocte)
• Metabolised by CYP2D6, 1A2, and 3A4 but is a weak inhibitor of these enzymes - low risk of raising bisoprolol levels
• Caution: One published case report showed an INR rise to 5.9 after mirtazapine addition to warfarin. While the patient is on apixaban (not warfarin, and INR monitoring is not relevant), some degree of pharmacodynamic interaction with apixaban cannot be excluded; monitoring is warranted

Agents to Avoid or Use with Caution

Non-Pharmacological Adjuncts

• Decreased social life → Interpersonal Therapy (IPT) or behavioural activation
• High anxiety → CBT for anxiety in older adults
• Sleep problems → Sleep hygiene, CBT-I; avoid benzodiazepines (fall risk); short-term orexin antagonists (suvorexant) can be considered per Kaplan guidelines

Monitoring Plan

• Platelet count at baseline and 4 weeks - watch for any worsening of ITP
• Renal function / sodium - SSRIs can cause SIADH/hyponatremia (much more common in older adults); check U&E at 2-4 weeks
• Signs of bleeding - bruising, GI symptoms, haematuria
• Response at 4 weeks - late-life depression responds more slowly (full remission 8-12 weeks); do not switch prematurely
• Bisoprolol tolerability - heart rate and BP monitoring, especially in the first few weeks

Summary Recommendation

First choice: Sertraline 25 mg/day, titrate to 50 mg/day after 2 weeks if tolerated

• Best cardiac safety profile (no QTc effect, no bisoprolol interaction)
• Lowest CYP interaction burden with apixaban
• Proven efficacy in late-life depression
• If sleep and anxiety are prominent and persistent, add or switch to Mirtazapine 7.5-15 mg nocte

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Pharmacotherapy for Geriatric Depression
• The Maudsley Prescribing Guidelines in Psychiatry, 15th ed. - Cardiac Effects of Antidepressants (Table 3.13), Geriatric Dosing Table
• Bradley and Daroff's Neurology in Clinical Practice - Mirtazapine in older adults

Note: This information is for clinical reference. Prescribing decisions should always be made by a licensed clinician with full knowledge of the individual patient's current medications, comorbidities, and clinical status. An ITP haematology review is worth considering before initiating any SSRI given the combined bleeding risk with Apixaban.